Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer's Disease
Overview
Neurology
Affiliations
Alzheimer's disease (AD) is a chronic neurodegenerative disease that has been recognized as one of the most intractable medical problems with heavy social and economic costs. Amyloid-β (Aβ) has been identified as a major factor that participates in AD progression through its neurotoxic effects. The major mechanism of Aβ-induced neurotoxicity is by interacting with membrane receptors and subsequent triggering of aberrant cellular signaling. Besides, Aβ transporters also plays an important role by affecting Aβ homeostasis. Thus, these Aβ receptors and transporters are potential targets for the development of AD therapies. Here, we summarize the reported therapeutic strategies targeting Aβ receptors and transporters to provide a molecular basis for future rational design of anti-AD agents.
Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer's Disease-Are There Connections?.
Fulek M, Hachiya N, Gachowska M, Beszlej J, Bartoszewska E, Kurpas D Int J Mol Sci. 2025; 26(5).
PMID: 40076721 PMC: 11900156. DOI: 10.3390/ijms26052097.
Sarkar S Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39589529 DOI: 10.1007/s00210-024-03595-6.
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification.
Song C, Huang W, Zhang P, Shi J, Yu T, Wang J Transl Neurodegener. 2024; 13(1):54.
PMID: 39497162 PMC: 11533276. DOI: 10.1186/s40035-024-00442-9.
Xiaojuan L, Hongmei L, Zhuxin W, Xiaoqin L, Lanbing D, Dan L Heliyon. 2024; 10(15):e35394.
PMID: 39170207 PMC: 11336570. DOI: 10.1016/j.heliyon.2024.e35394.
Effect of β-amyloid on blood-brain barrier properties and function.
Petrushanko I, Mitkevich V, Makarov A Biophys Rev. 2023; 15(2):183-197.
PMID: 37124923 PMC: 10133432. DOI: 10.1007/s12551-023-01052-x.